Filter
152
Filtered Results: 152
Text search:
EMA
European
Medicines
Agency
Featured
Recommendations
18
New Publications
33
Language
Document type
No document type
55
Guidelines
40
Studies & Reports
25
Fact sheets
21
Manuals
6
Situation Updates
2
Strategic & Response Plan
2
Training Material
1
Countries / Regions
Germany
7
Western and Central Europe
5
West and Central Africa
3
Brazil
2
Colombia
2
East and Southern Africa
2
Africa
2
Eastern Europe
2
Guinea
1
Sierra Leone
1
Liberia
1
Congo, Democratic Republic of
1
Ethiopia
1
Uganda
1
Philippines
1
India
1
Nepal
1
Zambia
1
Kenya
1
Cambodia
1
Thailand
1
Indonesia
1
Bangladesh
1
Argentina
1
Peru
1
Ukraine
1
Ecuador
1
Chile
1
Latin America and the Carribbean
1
Paraguay
1
Venezuela
1
Tajikistan
1
Russia
1
Denmark
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
30
Countries
26
Pharmacy & Technologies
6
Women & Child Health
5
Capacity Building
1
Public Health
1
Key Resources
1
Toolboxes
COVID-19
38
AMR
28
HIV
10
Ebola
9
TB
9
Pharmacy
8
Rapid Response
7
Mental Health
4
Planetary Health
4
Refugee
3
NTDs
3
Zika
2
Disability
1
Natural Hazards
1
The second ECDC/EFSA/EMA joint report on the integrated analysis of antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in bacteria from humans and food-producing animals addressed data obtained by the Agencies’ EU-wide surveillance...
This guideline provides advice in regards to applications for Marketing Authorisations for antimicrobial veterinary medicinal products (VMPs) on the data required and the methodology to be used for performing an assessment of the risk to public health from antimicrobial resistance (AMR) due to use o...
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments and vaccines to ...
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim re...
An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages
18 Febr. 2021
23 April 2020EMA/202483/2020 Rev
Chloroquine and hydroxychloroquine are known to potentially cause heart rhythm problems, and these could be exacerbated if treatment is combined with other medicines, such as the antibiotic azithromycin, that have s...
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...
The ECDC, the EFSA and the EMA have for the first time jointly explored associations between consumption of antimicrobials in humans and food-producing animals, and antimicrobial resistance in bacteria from humans and food-producing animals, using 2...
7 June 2021
The Africa Regulatory Taskforce is a joint effort established by the Africa Centres for Disease Control and Prevention (Africa CDC), the African Union Development Agency (AUDA-NEPAD) coordinated African ... Regulatory Harmonization (AMRH) Initiative, and the World Health Organisation’s (WHO) African Vaccine Regulatory Forum (AVAREF) to enable and provide support for an effective regulatory framework for COVID-19 Vaccines in Africa.
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 ... Drug Report package.
Available in different languages: http://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en
Table of contents:
- Preface
- Introductory note and acknowledgements
- Commentary
- Chapter 1: Drug supply and the market
- Chapter 2: Drug use prevalence and trends
- Chapter 3: Drug-related harms and responses
- Annex: National data tables
Available in 24 languages on:
http://www.emcdd...
The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I...
This report provides an overview of the main findings of the 2019–2020 harmonised AMR monitoring in the main food-producing animal populations monitored, in carcase/meat samples and in humans. Where available, monitoring data obtained from pigs, calves, broilers, laying hens and turkeys, as well a...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to ... is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pandemic laid this inequity bare, it also saw the pharmaceutical industry develop and bring new vaccines and treat- ments to market at unprecedented speed. As the world emerges from the worst
of this crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...
